Ambryon Biosciences

Spark100 Serotype

Bioengineered clinical AAV capsid derived from AAVrh.74 for hemophilia B gene therapy. Optimized for liver transduction with favorable seroprevalence profile.

TropismLiver (highly efficient), hepatocytes

Characteristics

Bioengineered from AAVrh.74 template. Optimized for high liver transduction efficiency. Very low pre-existing neutralizing antibody prevalence in humans. Favorable biodistribution profile with liver specificity. Reduced off-target transduction. Strong clinical safety and efficacy data. Used in SPK-9001 hemophilia B program.

Applications

Hemophilia B gene therapy (clinical trials with sustained Factor IX expression). Liver-directed gene therapy in antibody-positive populations. Clinical hemophilia programs. Demonstrates successful AAV bioengineering for clinical translation.

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Majowicz et al. (2019). Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5ch and AAV1. Mol Ther Methods Clin Dev — Majowicz 2019 Spark100
  2. 2.George et al. (2017). Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med — George 2017 Spark100

Identifiers & revision